Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

24.35
-1.0800-4.25%
Pre-market: 25.351.00+4.12%08:29 EDT
Volume:1.14M
Turnover:28.37M
Market Cap:1.67B
PE:-10.13
High:26.15
Open:25.58
Low:24.15
Close:25.43
52wk High:40.65
52wk Low:12.12
Shares:68.76M
Float Shares:44.33M
Volume Ratio:0.43
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:4.73
PE(LYR):-12.10

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Tyra Bioscience (TYRA)

TIPRANKS
·
Sep 08

U.S. Small Caps Close Up; Tyra Biosciences Climbs Highest

Dow Jones
·
Sep 05

Tyra Biosciences Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 05

Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45

TIPRANKS
·
Sep 04

Tyra Biosciences to Present Initial Phase 2 Surf302 Data for Oral Dabogratinib in Intermediate-Risk Bladder Cancer on Sept. 9

Reuters
·
Sep 04

Tyra Bioscience (TYRA) Gets a Buy from Bank of America Securities

TIPRANKS
·
Aug 11

BofA Adjusts Price Target on Tyra Bioscience to $39 From $42

MT Newswires Live
·
Aug 11

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Tyra Biosciences price target lowered to $42 from $44 at Jefferies

TIPRANKS
·
Aug 06

Tyra Biosciences delayed cancer data by one month, says JonesResearch

TIPRANKS
·
Aug 06

Tyra Biosciences falls 20% after pushing data readout to September from August

TIPRANKS
·
Aug 06

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)

TIPRANKS
·
Aug 05

Tyra Biosciences Q2 EPS $(0.69) Misses $(0.65) Estimate

Benzinga Earnings
·
Aug 05

Tyra Biosciences - Amends Sales Agreement on Aug 4, 2026 to Increase Maximum Offering Price for Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 05

Tyra Biosciences - May Offer and Sell up to $250 Mln of Common Stock Under Amended Sales Agreement - SEC Filing

THOMSON REUTERS
·
Aug 05

Tyra Biosciences Q2 FY26 Net Loss Widens to $45.56 Million; R&D Expenses Climb to $39.2 Million

Reuters
·
Aug 05

Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial

TIPRANKS
·
Jul 30

Analyst Maintains Buy on Tyra Biosciences, Reiterates $50 Price Target on NMIBC Opportunity

TIPRANKS
·
Jul 22